Clinical Trial Update: Clinical Study to Evaluate the Maximum Tolerated Dose of BAY87-2243 in Patients With Advanced Malignancies [Phase 1]

View source ↗

Summary

This clinical trial update reports termination of a Phase 1 study evaluating the maximum tolerated dose of BAY87-2243 in patients with advanced cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• BAY87-2243

Snippet

Sponsor: Bayer | Conditions: Neoplasms | Phase 1 | Status: TERMINATED